Disc Medicine to Participate in Upcoming Investor Conferences
August 30, 2024 08:00 ET
|
Disc Medicine Inc
WATERTOWN, Mass., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of...
Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update
August 08, 2024 08:00 ET
|
Disc Medicine Inc
Presented positive data for all three programs at the European Hematology Association (EHA) 2024 Congress; demonstrated potential efficacy for bitopertin in erythropoietic protoporphyria (EPP) and...
Disc Medicine Announces Underwritten Offering of Common Stock
June 14, 2024 08:03 ET
|
Disc Medicine Inc
WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization...
Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress
June 14, 2024 07:30 ET
|
Disc Medicine Inc
Updated analyses of data from AURORA and BEACON studies further demonstrate clinical activity of bitopertin across multiple measures of erythropoietic protoporphyria (EPP) and support development path...
Disc Medicine to Participate in the Jefferies Global Healthcare Conference
May 30, 2024 09:00 ET
|
Disc Medicine Inc
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress
May 14, 2024 10:30 ET
|
Disc Medicine Inc
Additional analyses of data from AURORA, as well as the full adult data set from BEACONUpdated data from the ongoing Phase 1b study of DISC-0974 in myelofibrosis (MF) patients with anemia, including a...
Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference
May 13, 2024 08:00 ET
|
Disc Medicine Inc
WATERTOWN, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update
May 09, 2024 08:00 ET
|
Disc Medicine Inc
Presented top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), in April 2024On track to deliver additional analyses from BEACON and...
Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)
April 01, 2024 08:00 ET
|
Disc Medicine Inc
Met primary endpoint, demonstrating dose-dependent, statistically significant reductions in protoporphyrin IX (PPIX) compared to placebo in both 20 mg and 60 mg dose groupsImproved measures of light...
Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
March 21, 2024 08:00 ET
|
Disc Medicine Inc
Top-line results from AURORA, the placebo-controlled phase 2 study of bitopertin in erythropoietic porphyrias (EPP), expected March / April 2024On track to deliver multiple read-outs in 2024,...